Economy
Enlila Health Acquires U.S. Biotech Leader Crescenta
724FinanceHakan Çelik

Work Capital’s biotechnology strategy is amplified as Enlila Health acquires Crescenta Biosciences in the United States.
Biotech Revolution: Enlila’s Acquisition of Crescenta
Enlila Health, a subsidiary of Türkiye İş Bankası Group, has taken majority control of Crescenta Biosciences through a capital increase backed by a 10% stake from Harvard University, boosting its international competitiveness in biotechnology.
Strategic Financial Leap: Harvard Partnership and Capital Increase
Operational Synergy: Scientific Foundations and Clinical Objectives
Enlila’s Harvard University academic infrastructure merges with Crescenta’s focus on fatty‑acid‑binding proteins and immunometabolism, accelerating the transition of deep‑tech projects into clinical phases.
Market Reaction: Investor and Competitive Attention
Future Outlook: Implications for Turkey’s Biotech Ecosystem
The importance of strategic investments to enhance Turkey’s global competitiveness in biotechnology goes beyond capital flow; it is measured by fostering academic collaboration and strengthening the innovation ecosystem. The union of Enlila and Crescenta exemplifies this effort, setting a model for sustainable growth locally and globally.